Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 178-188

  Singh, Gurinder ^a   Pai, Roopa S ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Anti retroviral drugs; Bioavailability; Enterohepatic recirculation; HIV AIDS; Nanostructured delivery; Trans resveratrol

Indexed keywords

ANTI-RETROVIRAL DRUGS; BIOAVAILABILITY; HIV/AIDS; NANO-STRUCTURED; RECIRCULATIONS; TRANS-RESVERATROL;

NANOCAPSULE; NANOMATERIAL; RESVERATROL; SOLID LIPID NANOPARTICLE; ANTIOXIDANT; STILBENE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; EMULSION; ENTEROHEPATIC CIRCULATION; HUMAN; NONHUMAN; POLYMERIZATION; REVIEW; ACQUIRED IMMUNODEFICIENCY SYNDROME; CHEMISTRY; HIV INFECTIONS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; NANOSTRUCTURES; STILBENES;

EID: 84907197092     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.002     Document Type: Review

References (156)

1. C.A. De. La. Lastra., and I. Villegas Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications Mol. Nutr. Food Res. 49 2005 405 430
2. L. Fremont Biological effects of resveratrol Life Sci. 66 2000 663 673
3. M.J. Takaoka Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.) J. Faculty Sci. Hokkaido Im. Univ. 3 1940 1 16
4. S. Nonomura, H. Kanagawa, and A. Makimoto Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum Sieb. et Zucc.) Yakugaku Zasshi 83 1963 988 990
5. P. Langcake, and R.J. Pryce The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury Physiol. Plant Pathol. 9 1976 77 86
6. E.H. Siemann, and L.L. Creasy Concentration of the phytoalexin resveratrol in wine Am. J. Enol. Vitic. 43 1992 49 52
7. M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, and J.M. Pezzuto Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 1997 218 220
8. S.P. Fraser, A. Peters, S.F. Jones, D. Mukhey, and M.B. Djamgoz Resveratrol: inhibitory effects on metastatic cell behaviors and voltage-gated na(+) channel activity in rat prostate cancer in vitro Nutr. Cancer. 66 2014 1047 1058
9. S. Fulda Resveratrol and derivatives for the prevention and treatment of cancer Drug Discov. Today 15 2010 757 765
10. D.J. Boocock, G.E. Faust, K.R. Patel, A.M. Schinas, V.A. Brown, M.P. Ducharme, T.D. Booth, J.A. Crowell, M. Perloff, A.J. Gescher, W.P. Steward, and D.E. Brenner Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent Cancer Epidemiol. Biomarkers Prev. 16 2007 1246 1252
11. N.K. Narayanan, D. Nargi, C. Randolph, and B.A. Narayanan Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice Int. J. Cancer 125 2009 1 8
12. Y. Qin, Z. Ma, X. Dang, W. Li, and Q. Ma Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway Mol. Med. Rep. 2014 10.3892/mmr.2014.2511
13. S. Bradamante, L. Barenghi, and A. Villa Cardiovascular protective effects of resveratrol Cardiovasc. Drug Rev. 22 2004 169 188
14. Q. Wang, J. Xu, G.E. Rottinghaus, A. Simonyi, D. Lubahn, G.Y. Sun, and A.Y. Sun Resveratrol protects against global cerebral ischemic injury in gerbils Brain Res. 958 2002 439 447
15. K. Sinha, G. Chaudhary, and Y.K. Gupta Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats Life Sci. 71 2002 655 665
16. A. Heredia, C. Davis, and R. Redfield Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol J. Acquir. Immune Defic. Syndr. 25 2000 246 255
17. O. Touzet, and A. Philips Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation AIDS 24 2010 1437 1447
18. K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. Wood, R.E. Zipkin, P. Chung, A. Kisielewski, L.L. Zhang, B. Scherer, and D.A. Sinclair Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
19. D.R. Valenzano, E. Terzibasi, T. Genade, A. Cattaneo, L. Domenici, and A. Cellerino Resveratrol prolongs lifespan and retards the onset of age-related markers in a short lived vertebrate Curr. Biol. 16 2006 296 300
20. A.J. Baur, and D.A. Sinclair Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. 500 2006 493 506
21. B.B. Aggarwal, A. Bhardwaj, R.S. Aggarwal, N.P. Seeram, S. Shishodia, and Y. Takada Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies Anticancer Res. 24 2004 2783 2840
22. P. Langcake, and R.J. Pryce The production of resveratrol by Vitis vinifera and other members of the vitaceae as a response to infection and injury Physiol. Plant Pathol. 9 1976 77 86
23. S. Das, and K.-Y. Ng Quantification of trans-resveratrol in rat plasma by a simple and sensitive high performance liquid chromatography method and its application in pre-clinical study J. Liq. Chromatogr. Relat. Technol. 34 2011 1399 1414
24. M.A. Vian, V. Tomao, S. Gallet, P.O. Coulomb, and J.M. Lacombe Simple and rapid method for cis- and trans-resveratrol and piceid isomers determination in wine by high-performance liquid chromatography using chromolith columns J. Chromatogr. A 1085 2005 224 229
25. K.P.L. Bhat, J.W. Kosmeder II, and J.M. Pezzuto Biological effects of resveratrol Antioxid. Redox Signal. 3 2001 1041 1064
26. P. Kopp Resveratrol a phytoestrogen found in red wine. A possible explanation for the conundrum of the French paradox? Eur. J. Endocrinol. 138 1998 619 620
27. H. Zhuang, Y.S. Kim, R.C. Koehler, and S. Dore Potential mechanism by which resveratrol, a red wine constituent, protects neurons Ann. N. Y. Acad. Sci. 993 2003 276 286
28. L. Buryanovskyy, Y. Fu, M. Boyd, Y. Ma, T.C. Hsieh, J.M. Wu, and Z. Zhang Crystal structure of quinone reductase 2 in complex with resveratrol Biochemistry 43 2004 11417 11426
29. A. Amri, J.C. Chaumeil, S. Sfar, and C. Charrueau Administration of resveratrol: what formulation solutions to bioavailability limitations J. Control. Release 158 2012 182 193
30. L. Le Corre, P. Fustier, N. Chalabi, Y.J. Bignon, and D. Bernard-Gallon Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines Clin. Chim. Acta 344 2004 115 121
31. J.K. Kundu, and Y.J. Surh Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives Cancer Lett. 269 2008 243 261
32. J.F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.P. Moreau, and M.P. Ducharme Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J. Pharmacol. Exp. Ther. 302 2002 369 373
33. J. Gambini, R. Lopez-Grueso, G. Olaso-Gonzalez, M. Ingles, K. Abdelazid, M. El Alami, V. Bonet-Costa, C. Borrás, and J. Vina Resveratrol: distribution, properties and perspectives Rev. Esp. Geriatr. Gerontol. 48 2013 79 88
34. A. Agostini, S. Balzi, Composition containing resveratrol and essential oil of cloves for the treatment of Itching, US 2014/0079835 A1, 2014.
35. G. Marder, Hydrocortisone nano technological delivery, US 2014/0073616 A1, 2014.
36. G. Pifferi, P. Anzaghi, R. Stefli, Resveratrol-phospholipids complexes, their preparation, and pharmaceutical and cosmetic composition containing same, US 2004/0116386 A1, 2004.
37. M. Duan, H. Zhou, Z. Yan, Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof, US 2010/0297199 A1, 2010.
38. W.J. Lunsmann, P. Elliott, P. Lambert, Resveratrol formulations, US 2011/0009496 A1, 2011.
39. G. Miquel, Microemulsion of polar antioxidants in edible oils, EP 1 829 452 A1, 2007.
40. C.C. Giosan, Aqueous compositions comprising resveratrol and methods for making them, US 2013/0023590 A1, 2013.
41. T.R. Dugas, A. Khandelwal, J.J. Kleinedler III, J.D. Foley, Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity, US 2013/0030518 A1, 2013.
42. U. Speck, M.C. Berg, Coated formulation for scoring or cutting balloon catheters, US 2013/0046231 A1, 2013.
43. A.A. Souto, M.M. Campos, F.B. Marrone, R.B. Madeira de silva, I.D.S. Maciel, Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and /or pharmaceutical product, and method for enhancing the potential of resveratrol, US 2013/0040920 A1, 2013.
44. J.V. Cappello, Anti-aging formulations, US 2013/0115195A1, 2013.
45. J.W. Finley, J.W. Finley, I. Mezine, M. Kehrer II James, J. Justice II Robert, Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest, US2010/0197801 A1, 2010.
46. W.F. Sardi, Compositions containing resveratrol and nucleotides, WO2013074948 A1, 2013.
47. C.R. George, P. Krupa, C. Marieann, B.C. Annette, P. Sreekumar, S. Uma, W.R. Lynn, I. Koichi, P.L. Rose, Cosmetic compositions containing resveratrol, US6270780, 2001.
48. K. Eric, Enhanced bioactive formulations of resveratrol, CA2748344 A1, 2010.
49. S. Pillai, R.G. Carson, K. Patel, M. Carlomusto, C.A. Bosko, Cosmetic compositions containing resveratrol, ZA1998/06039, 2000.
50. J. Pezzuto, R. Moon, M-S. Jang, A. Ouali, S. Lin, K.Barillas, Pharmaceutical formulations of resveratrol, US20020173472 A1, 2002.
51. A. Saxena, C.F. Wertz, V. Ann O'neill, J.S. Jensen, K.R. Lundell, Solid dispersion comprising resveratrol, WO2010102245, 2010.
52. M. DeRosa, M. Rossi, Use of resveratrol as sunscreen, US20040009197 A1, 2004.
53. C-C. Chen, S. Diguet, B.H. Leuenberger, K.Urban, Compositions containing resveratrol and pectin, US20110039945 B2, 2011.
54. S. Pillai, M.N. Mahajan, S.P. Granger, D.J. Pocalyko, M. Barratt. Cosmetic compositions containing resveratrol and retinoids, US6358517 B1, 2002.
55. R.S. Grant, K. Lindbeck. Pharmaceutical compositions of resveratrol, WO2013056298, 2012.
56. G. Moretti, L. Mosca. Association of resveratrol and carboxymethylglucan, EP2674155 A1, 2013.
57. P. Clement, M. Teris. Novel resveratrol compositions, CA2629979 A1, 2009.
58. Q. Shi, R. Jin, J. Chen, M. Chen, H. Li, L. Lv, B. Gao, Flexible liposome of resveratrol and preparation method thereof, EP2431023 A4, 2012.
59. E. Kuhrts, Enhanced bioactive formulations of resveratrol, WO2010062824, 2010.
60. G. Pifferi, P. Anzaghi, R. Stefli. Resveratrol-phospholipids complexes, WO2002072591, 2002.
61. S.A. Arigony. Resveratrol complex and process for the preparation, CA2694343 A1, 2009.
62. V. Berl, Formulations of ubiquinol and resveratrol esters, US20120088829 A1, 2012.
63. D.H. Maes, F. Mohammadi, L. Qu, A. Czarnota, T. Mammone, L. Declercq, J.R. Zecchino, US20090035237 A1, 2009.
64. M. Duan, H. Zhou, Z. Yan, Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof, US20100297199 B2, 2010.
65. S.A. Arigony, Process for the preparation of a water-soluble complex having resveratrol compounds; products comprising said complex; and uses thereof, US20100204179, 2010.
66. A.S. Polans, L. Subramanian, R. Vakil, G.S. Kwon, Water-soluble formulations of resveratrol and uses thereof, WO2010059628, 2010.
67. J. Yang, Resveratrol nanometer preparation and preparation method thereof, CN102106816 A, 2011.
68. W. Yang, Y. Liu, Y. Yang, Self-emulsified resveratrol soft capsules, CN101961323 A, 2011.
69. Q. Shi, R. Jin, J. Chen, M. Chen, H. Li, L. Lu, B. Gao, Resveratrol flexible liposome and preparation method thereof, CN101874763 A, 2010.
70. J. Chen, J. Jie, Y. Zhang, L. Yue, Qi. Zhao, B. Gao, L. Ma, Resveratrol injection solution and intravenous injection, CN102188370 B, 2011.
71. J. Chen, X. Zhang, Y. Le, J. Wang, H. Huang, Y. Geng, Z. Zhang, W. Zhu, Resveratrol nanoscale dispersoid and preparation method thereof, CN102614127 A, 2012.
72. H. Wei, Resveratrol pellet and preparation method thereof, CN101703479 A, 2010.
73. E.A. Oganesjan, N.S. Vikhrieva, S.J. Leshkov, Compositions containing resveratrol particles; and method for making thereof (versions), RU02373926 C1, 2009.
74. W.Q. Ouyang, B. Yang, Resveratrol nano emulsion anti-cancer medicine, CN101214225 A, 2008.
75. Q. Xia, W. Zhao, Resveratrol nanostructured lipid carrier and preparation method thereof, CN102614091 A, 2012.
76. Y. Dong, L. Ai, Solid dispersion of resveratrol and glycosides and preparation method thereof, CN101292966 A, 2008.
77. Q. Shi, R. Jin, J. Chen, M. Chen, H. Li, L. Lv, B. Gao, Flexible liposome of resveratrol and preparation method thereof, WO2010124540, 2010.
78. Y. Zhou, Oral administration nano-drug administration system of resveratrol, CN101317832 B, 2008.
79. T. Tian, Method for improving bioavailability of resveratrol, CN102885780 A, 2013.
80. W. Li, A. Li, W. Chen, Z. Zhang, Preparation method and application of resveratrol freeze-dried polymer micelle, CN102755298 A, 2012.
81. H. Yu, D. Liu, H. Sun, Method for preparing hydrophilic resveratrol by use of PEG (polyethylene glycol) modification technology, CN102887994 A, 2013.
82. J. Yao, X. Wu, Y. Wang, Y. Ni, Preparation method of freeze-dried resveratrol albumin powder, CN101658499 A, 2010.
83. M. Duan, H. Zhou, Resveratrol phospholipid composite nano-emulsion and preparation method and application thereof, CN101579291 B, 2009.
84. C.T. Kim, C.J. Kim, Y.J. Cho, A.J. Choi, Nanoemulsion employing resveratrol and middle-chain fatty acid triglyceride, nanoparticle, and manufacturing method thereof, KR1020090132357, 2009.
85. Z. Guo, H. Wei, J. Zhang, H. Zheng, Preparation technology for water-soluble resveratrol particle, and product and application thereof, CN101759531 B, 2010.
86. R. Suo, J. Wang, Method for improving stability and water solubility of resveratrol and application thereof, CN101927148 A, 2010.
87. K. Liu, X. Zhao, H. Xu, Y. Ma, X. Zou, W. Huang, Resveratrol hydrophilic conjugate, its preparation method and application, CN102766258 A, 2012.
88. H. Shen, Z. Zhao, Method for preparing resveratrol sustained-release capsule capable of preventing rheumatoid arthritis, CN101693022 B, 2010.
89. H. Bu, Y. Han, Y. Zhang, H. Zheng, PEG (Polyethylene Glycol), mPEG (Methoxy Polyethylene glycol) chemical modifier and method thereof for preparing water-soluble resveratrol prodrug, CN101870769 B, 2010.
90. S.D. Li, and L. Huang Pharmacokinetics and biodistribution of nanoparticles Mol. Pharm. 5 2008 496 504
91. R. Singh, and J.W. Lillard Jr. Nanoparticle-based targeted drug delivery Exp. Mol. Pathol. 86 2009 215 223
92. L. Plapied, N. Duhem, A. des. Rieux, and V. Preat Fate of polymeric nanocarriers for oral drug delivery Curr. Opin. Colloid Interface Sci. 16 2011 228 237
93. O.C. Farokhzad, and R. Langer Impact of nanotechnology on drug delivery ACS Nano 3 2009 16 20
94. J.B. Hall, M.A. Dobrovolskaia, A.K. Patri, and S.E. McNeil Characterization of nanoparticles for therapeutics Nanomedicine (London) 2 2007 789 803
95. A. des Rieux, V. Fievez, M. Garinot, Y.J. Schneider, and V. Preat Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach J. Control. Release 116 9 2006 1 27
96. A. Kumari, S.K. Yadav, and S.C. Yadav Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf. B: Biointerfaces 75 2010 1 18
97. R. Langer Drug delivery and targeting Nature 392 Suppl. 6679 1998 5 10
98. G. Singh, and R.S. Pai Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential Expert Opin. Drug Deliv. 11 2014 647 659
99. G. Singh, and R.S. Pai In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration J. Pharm. Pharmacol. 66 2014 1062 1076
100. G. Singh, and R.S. Pai Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies Drug Deliv. 2014 10.3109/10717544.2014.885616
101. G. Singh, R.S. Pai, and V. Pandit In vivo pharmacokinetic applicability of a simple and validated HPLC method for orally administered trans-resveratrol loaded polymeric nanoparticles to rats J. Pharm. Invest. 44 2014 69 78
102. A.R. Neves, M. Luucio, S. Martins, J.L. Lima, and S. Reis Novel resveratrol nano delivery systems based on lipid nanoparticles to enhance its oral bioavailability Int. J. Nanomedicine 8 2013 177 187
103. S. Kim, W.K. Ng, Y. Dong, S. Das, and R.B.H. Tan Preparation and physicochemical characterization of trans-resveratrol nanoparticles by temperature-controlled antisolvent precipitation J. Food Eng. 108 2012 37 42
104. G. da Rocha Lindner, N.M. Khalil, and R.M. Mainardes Resveratrol-loaded polymeric nanoparticles: validation of an HPLC-PDA method to determine the drug entrapment and evaluation of its antioxidant activity Scientific World Journal Volume 2013 2013 Article ID 506083, 9 pages, http://dx.doi.org/10.1155/2013/506083
105. T.K. Vyas, L. Shah, and M.M. Amiji Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites Expert Opin. Drug Deliv. 3 2006 613 628
106. C.P. Reis, R.J. Neufeld, A.J. Ribeiro, and F. Veiga Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2 2006 53 65
107. W.H. De Jong, and P.J. Borm Drug delivery and nanoparticles: applications and hazards Int. J. Nanomedicine 3 2008 133 149
108. J. Shao, X. Li, X. Lu, C. Jiang, Y. Hu, Q. Li, Y. You, and Z. Fu Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels Colloids Surf. B: Biointerfaces 72 2009 40 47
109. X. Lu, C. Ji, H. Xu, X. Li, H. Ding, M. Ye, Z. Zhu, D. Ding, X. Jiang, X. Ding, and X. Guo Resveratrol-loaded polymeric micelles protect cells from Aβ-induced oxidative stress Int. J. Pharm. 375 2009 89 96
110. E.A. Oganesyan, I.I. Miroshnichenko, N.S. Vikhrieva, A.A. Lyashenko, and S.Yu. Leshkov Use of nanoparticles to increase the systemic bioavailability of trans-resveratrol Pharm. Chem. J. 44 2010 74 76
111. Y. Zu, Y. Zhang, W. Wang, X. Zhao, X. Han, K. Wang, and Y. Ge Preparation and in vitro/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles Drug Deliv. 2014 10.3109/10717544.2014.924167
112. U.M. Musazzi, I. Youm, J.B. Murowchick, M.J. Ezoulin, and B.B. Youan Resveratrol-loaded nanocarriers: formulation, optimization, characterization and in vitro toxicity on cochlear cells Colloids Surf. B: Biointerfaces 2014 Apr 13 10.1016/j.colsurfb.2014.03.054
113. A.A. Date, M.D. Joshi, and V.B. Patravale Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 505 521
114. R.H. Muller, R. Shegokar, and C.M. Keck 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications Curr. Drug Discov. Technol. 8 2011 207 227
115. K. Teskac, and J. Kristl The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol Int. J. Pharm. 390 2010 61 69
116. D. Pandita, S. Kumar, N. Poonia, and V. Lather Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol Food Res. Int. 2014 10.1016/j.foodres.2014.05.059
117. D. Pando, C. Caddeo, M. Manconi, A.M. Fadda, and C. Pazos Nanodesign of olein vesicles for the topical delivery of the antioxidant resveratrol J. Pharm. Pharmacol. 65 2013 1158 1167
118. B. Singh, S. Beg, R.K. Khurana, P.S. Sandhu, R. Kaur, and O.P. Katare Recent advances in self-emulsifying drug delivery systems (SEDDS) Crit. Rev. Ther. Drug Carrier Syst. 31 2014 89 153
119. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
120. K. Kohli, S. Chopra, D. Dhar, S. Arora, and R. Khar Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability Drug Discov. Today 15 2010 958 965
121. C.W. Pouton Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification Int. J. Pharm. 27 1985 335 348
122. J. Zhang, Y. Lv, S. Zhao, B. Wang, M. Tan, H. Xie, G. Lv, and X. Ma Effect of lipolysis on drug release from self-microemulsifying drug delivery systems (SMEDDS) with different core/shell drug location AAPS PharmSciTech 15 2014 731 740
123. K. Bolko, A. Zvonar, and M. Gašperlin Mixed lipid phase SMEDDS as an innovative approach to enhance resveratrol solubility Drug Dev. Ind. Pharm. 40 2014 102 109
124. A. Amri, S. Le Clanche, P. Thérond, D. Bonnefont-Rousselot, D. Borderie, R. Lai-Kuen, J.C. Chaumeil, S. Sfar, and C. Charrueau Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death Eur. J. Pharm. Biopharm. 86 2013 418 426
125. K.A. Ansari, P.R. Vavia, F. Trotta, and R. Cavalli Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study AAPS PharmSciTech 12 2011 279 286
126. A. Segal, G. Gregoriadis, and C.D. Black Liposomes as vehicles for the local release of drugs Clin. Sci. Mol. Med. 49 1975 99 106
127. N.K. Jain, V. Mishra, and N.K. Mehra Targeted drug delivery to macrophages Expert Opin. Drug Deliv. 10 2013 353 367
128. J. Szebeni The interaction of liposomes with the complement system Crit. Rev. Ther. Drug Carrier Syst. 15 1998 57 88
129. J.S. Chang, M.J. Choi, T.Y. Kim, S.Y. Cho, and H.S. Cheong Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes Vaccine 17 1999 1540 1548
130. M. Coimbra, B. Isacchi, L. van Bloois, J.S. Torano, A. Ket, X. Wu, F. Broere, J.M. Metselaar, C.J. Rijcken, G. Storm, R. Bilia, and R.M. Schiffelers Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes Int. J. Pharm. 416 2011 433 442
131. S. Basavaraj, and G.V. Betageri Improved oral delivery of resveratrol using proliposomal formulation: investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol Expert Opin. Drug Deliv. 11 2014 493 503
132. C.F. Hung, J.K. Chen, M.H. Liao, H.M. Lo, and J.Y. Fang Development and evaluation of emulsion-liposome blends for resveratrol delivery J. Nanosci. Nanotechnol. 6 2006 2950 2958
133. C.F. Hung, C.L. Fang, M.H. Liao, and J.Y. Fang The effect of oil components on the physicochemical properties and drug delivery of emulsions: tocol emulsion versus lipid emulsion Int. J. Pharm. 335 2007 193 202
134. R.L. Frozza, A. Bernardi, K. Paese, J.B. Hoppe, T. da Silva, A.M. Battastini, A.R. Pohlmann, S.S. Guterres, and C. Salbego Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats J. Biomed. Nanotechnol. 6 2010 694 703
135. J. Fang, C.F. Hung, M.H. Liao, and C.C. Chien A study of the formulation design of acoustically active lipospheres as carriers for drug delivery Eur. J. Pharm. Biopharm. 67 2007 67 75
136. UNAIDS Report on the Global AIDS Epidemic 2008 United Nations Geneva, Switzerland
137. C.A. Hankins, and M.R. Dybul The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review Curr. Opin. HIV AIDS 8 2013 50 58
138. S.D. Mahajan, R. Aalinkeel, W.C. Law, J.L. Reynolds, B.B. Nair, D.E. Sykes, K.T. Yong, I. Roy, P.N. Prasad, and S.A. Schwartz Anti-HIV-1 nanotherapeutics: promises and challenges for the future Int. J. Nanomedicine 7 2012 5301 5314
139. V. Pirrone, B. Wigdahl, and F.C. Krebs The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1 Antivir. Res. 90 2011 168 182
140. A. Majid, R. Redfield, and B. Gilliam The use of preexposure prophylaxis treatments for HIV prophylaxis HIV/AIDS Res Palliative Care 4 2012 17 28
141. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf (accessed on 17/05/2014)
142. R.W. Buckheit Jr., K.M. Watson, K.M. Morrow, and A.S. Ham Development of topical microbicides to prevent the sexual transmission of HIV Antivir. Res. 85 2010 142 158
143. A.A. Date, and C.J. Destache A review of nanotechnological approaches for the prophylaxis of HIV/AIDS Biomaterials 34 2013 6202 6228
144. http://www.ncbi.nlm.nih.gov/pubmed/?term=RESVERATROL+HIV (accessed on 17/05/2014)
145. http://www.cehd.org/resveratrol-research/resveratrol-a-possible-tool-for-treating-hiv/ (accessed on 17/05/2014)
146. Z. Lin, J. Li, and D. Fang SIRT1 involvement in virus-mediated diseases JSM Microbiol. 2 2014 1 5
147. H.S. Zhang, and M.R. Wu SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase Virus Res. 146 2009 51 57
148. V. Krishnan, and S.L. Zeichner Host cell gene expression during HIV-1 latency and reactivation, and effects targeting genes differentially expressed in viral latency J. Virol. 78 2004 9458 9473
149. A. Heredia, C. Davis, M.N. Amin, N.M. Le, M.A. Wainberg, M. Oliveira, S.G. Deeks, L.X. Wang, and R.R. Redfield Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1 AIDS 28 2014 317 323
150. C.L. Clouser, J. Chauhan, M.A. Bess, J.L. van Oploo, D. Zhou, S. Dimick-Gray, L.M. Mansky, and S.E. Patterson Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine Bioorg. Med. Chem. Lett. 22 2012 6642 6646
151. Z.S. Piao, Y.B. Feng, L. Wang, X.Q. Zhang, and M. Lin Synthesis and HIV-1 inhibitory activity of natural products isolated from Gnetum parvifolium and their analogues Yao Xue Xue Bao 45 2010 1509 1515
152. H.S. Zhang, W.W. Sang, Y.O. Wang, and W. Liu Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation J. Cell. Biochem. 110 2010 1464 1470
153. H.S. Zhang, Y. Zhou, M.R. Wu, H.S. Zhou, and F. Xu Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activity Life Sci. 85 2009 484 489
154. M. Ndiaye, R. Kumar, and N. Ahmad Resveratrol in cancer management: where are we and where we go from here? Ann. N. Y. Acad. Sci. 1215 2011 144 149
155. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.L. Beaudeux Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 54 2010 7 16
156. O. Vang, N. Ahmad, C.A. Baile, J.A. Baur, K. Brown, A. Csiszar, D.K. Das, D. Delmas, C. Gottfried, H.Y. Lin, Q.Y. Ma, P. Mukhopadhyay, N. Nalini, J.M. Pezzuto, T. Richard, Y. Shukla, Y.J. Surh, T. Szekeres, T. Szkudelski, T. Walle, and J.M. Wu What is new for an old molecule? Systematic review and recommendations on the use of resveratrol PLoS One 6 2011 1 11